Stopping Flu Virus In Its Tracks

Main Category: Flu / Cold / SARS
Also Included In: MRSA / Drug Resistance
Article Date: 25 Feb 2013 - 0:00 PST

Current ratings for:
Stopping Flu Virus In Its Tracks

Patient / Public:not yet rated

Healthcare Prof:not yet rated


A new class of influenza drug has been shown effective against drug-resistant strains of the flu virus, according to a study led by University of British Columbia researchers.

Published online in the journal Science Express, the study details the development of a new drug candidate that prevents the flu virus from spreading from one cell to the next. The drug is shown to successfully treat mice with lethal strains of the flu virus.

In order to spread in the body, the flu virus first uses a protein, called hemagglutinin, to bind to the healthy cell's receptors. Once it has inserted its RNA and replicated, the virus uses an enzyme, called neuraminidase, to sever the connection and move on to the next healthy cell.

"Our drug agent uses the same approach as current flu treatments - by preventing neuraminidase from cutting its ties with the infected cell," says UBC Chemistry Prof. Steve Withers, the study's senior author. "But our agent latches onto this enzyme like a broken key, stuck in a lock, rendering it useless."

The World Health Organization estimates that influenza affects three to five million people globally each year, causing 250,000 to 500,000 deaths. In some pandemic years, the figure rose to millions.

"One of the major challenges of the current flu treatments is that new strains of the flu virus are becoming resistant, leaving us vulnerable to the next pandemic," says Withers, whose team includes researchers from Canada, the UK, and Australia.

"By taking advantage of the virus's own 'molecular machinery' to attach itself," Withers adds. "The new drug could remain effective longer, since resistant virus strains cannot arise without destroying their own mechanism for infection."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our flu / cold / sars section for the latest news on this subject.
Partners and funders
The research is funded by the Canadian Institutes of Health Research, the Canada Foundation for Innovation, the British Columbia Knowledge Development Fund.
The research team includes scientists from UBC, Simon Fraser University, and Centre for Disease Control in B.C., the University of Bath in the U.K. and CSIRO Materials Science and Engineering in Australia.
The new drug technology was developed in collaboration with The Centre for Drug Research and Development (CDRD) and has been advanced into CDRD Ventures' Inc., CDRD's commercialization vehicle, in order to secure private sector partners and investors to develop it through clinical trials.
The CDRD is Canada's national drug development and commercialization centre, which provides expertise and infrastructure to enable researchers from leading health research institutions to advance promising early-stage drug candidates. CDRD's mandate is to de-risk discoveries stemming from publicly-funded health research and transform them into viable investment opportunities for the private sector — thus successfully bridging the commercialization gap between academia and industry, and translating research discoveries into new therapies for patients.
University of British Columbia
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
University of British Columbia. "Stopping Flu Virus In Its Tracks." Medical News Today. MediLexicon, Intl., 25 Feb. 2013. Web.
25 May. 2013. <http://www.medicalnewstoday.com/releases/256744.php>

APA
University of British Columbia. (2013, February 25). "Stopping Flu Virus In Its Tracks." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/256744.php.

Please note: If no author information is provided, the source is cited instead.



Add Your Opinion On This Article

'Stopping Flu Virus In Its Tracks'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Flu / Cold / SARS

Most Popular Articles



Follow Our Flu News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Flu / Cold / SARS Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »